Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 2 od 4  
Back povratak na rezultate
Acta medica Medianae
2019, vol. 58, br. 4, str. 5-11
Imunohistohemijska analiza receptora 1 za vaskularni faktor rasta kod T1 karcinoma mokraćne bešike visokog gradusa i konkomitantnim in situ karcinomom
Ristić-Petrović Anaa ORCID, Stokanović Draganab ORCID, Krtinić Danec, Potić-Floranović Milenaa ORCID, Stojnev Slavicaa, Janković-Veličković Ljubinkaa ORCID
aUniverzitet u Nišu, Medicinski fakultet, Katedra Patologija
bUniverzitet u Nišu, Medicinski fakultet, Katedra Farmakologija sa toksikologijom
cUniverzitet u Nišu, Medicinski fakultet, Katedra Farmakologija sa toksikologijom + Klinički centar Niš, Klinika za onkologiju

e-adresa: anav.ristic@gmail.com
Projekat:
Etiologija, dijagnostika, prevencija, i terapija endemske nefropatije i sa njom povezanih tumora urotela - značaj istraživanja genoma i proteoma (MPNTR - 175092)

Ključne reči: angiogeneza; VEGFR1; karcinom mokraćne bešike; carcinoma in situ
Sažetak
Receptor 1 za vaskularni faktor rasta (VEGFR1) smanjuje angiogenetsku aktivnost vaskularnog faktora rasta (VEGF), ponašajući se kao lažni receptor za VEGF i ograničavajući njegovu dostupnost za prave angiogene receptore. Cilj rada je da se ustanovi značaj VEGFR1 ekspresije kod T1 karcinoma mokraćne bešike visokog gradusa (HGT1) sa konkomitantnim in situ karcinomom (CIS) i da se odredi imunohistohemijski marker koristan za praćenje "nepredvidivih" HGT1 bolesnika. Analizirano je 137 HGT1 karcinoma mokraćne bešike. Konkomitantni CIS dijagnostikovan je kod 21 bolesnika (15,33%). 137 parafinskih uzoraka uklopljeno je u tkivne mikroareje i obojeno zečjim monoklonalnim antitelom na VEGFR1 (N-term: Y103/Epitomics, razblaženje 1 : 250). Imunohistohemijska reakcija procenjivana je na sledeći način: negativna ekspresija ukoliko je obojeno ≤ 10% ćelija, a pozitivna ukoliko je obojeno > 10% ćelija. Procenjivana je i membranska i citoplazmatska ekspresija i skorirana prema skali od 0 do 3 (0 - nema bojenja; 1 - slabo bojenje; 2 - umereno; i 3 - intenzivno). Nakon praćenja u trajanju od 50 meseci, utvrđeno je da bolesnici sa HGT1 karcinomom mokraćne bešike i konkomitantnim CIS imaju ukupno manju stopu preživljavanja (p < 0,05), kao i manju ekspresiju VEGFR1 (p < 0,05). Bolesnici sa pozitivnim VEGFR1 imali su duži vremenski period bez recidiva (p < 0,01) i duže ukupno preživljavanje (p < 0,01). Istraživanje je pokazalo da procena VEGFR1 ekspresije može biti dijagnostička dopuna za odabir bolesnika sa HGT1 urotelnim karcinomom mokraćne bešike, kojima je neophodno intenzivnije praćenje, posebno ukoliko je prisutan i CIS.
Reference

Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., Bray, F. (2017) Bladder cancer incidence and mortality: A global overview and recent trends. European Urology, 71(1): 96-108

Babjuk, M., Böhle, A., Burger, M., Capoun, O., Cohen, D., Compérat, E.M., Hernández, V., Kaasinen, E., Palou, J., Rouprêt, M., van Rhijn, B.W.G., Shariat, S.F., Soukup, V., Sylvester, R.J., Zigeuner, R. (2017) Eau guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. European Urology, 71(3): 447-461

Boucher, J.M., Clark, R.P., Chong, D.C., Citrin, K.M., Wylie, L.A., Bautch, V.L. (2017) Dynamic alterations in decoy VEGF receptor-1 stability regulate angiogenesis. Nature Communications, 8(1): 15699-15699

Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Eeckt, V.K., Serretta, V., i dr. (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette Guerin: Results of a retrospective multicenter study of 2451 patients. Eur Urol, 67: 74-82

Hara, T., Takahashi, M., Gondo, T., Nagao, K., Ohmi, C., Sakano, S., Naito, K., Matsuyama, H. (2009) Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: Retrospective analysis of 173 Japanese cases. International Journal of Urology, 16(3): 293-298

Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M., Reuter, V.E. (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: Prostate and bladder tumours. European Urology, 70(1): 106-119

Jakse, G., Algaba, F., Malmström, P., Oosterlinck, W. (2004) A second-look TUR in T1 transitional cell carcinoma: Why?. European Urology, 45(5): 539-546

Janković-Veličković, L., Stojnev, S., Ristić-Petrović, A., Doličanin, Z., Hattori, T., Mukaisho, K., Stojanović, M., Stefanović, V. (2011) Pro-and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. Scientific World Journal, 11: 1699-1711

Kamat, A.M., Bagcioglu, M., Huri, E. (2017) What is new in non-muscle-invasive bladder cancer in 2016?. Türk Üroloji Dergisi/Turkish Journal of Urology, 43(1): 9-13

1

Kitamura, H., Kakehi, Y. (2015) Treatment and management of high-grade T1 bladder cancer: What should we do after second TUR?. Japanese Journal of Clinical Oncology, 45(4): 315-322

Kitamura, T. (2018) A negative regulator of metastasis promoting macrophages. Journal of Emergency and Critical Care Medicine, 2: 56-56

Kopparapu, P., Boorjian, S., Robinson, B., Downes, M., Gudas, L., Mongan, N., i dr. (2013) Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res, 33(6): 2381-90

Kulkarni, G.S., Hakenberg, O.W., Gschwend, J.E., Thalmann, G., Kassouf, W., Kamat, A., Zlotta, A. (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously t1g3) bladder cancer. European Urology, 57(1): 60-70

Lebok, P., Huber, J., Burandt, E., Lebeau, A., Marx, A.H., Terracciano, L., Heilenkötter, U., Jänicke, F., Müller, V., Paluchowski, P., Geist, S., Wilke, C., Simon, R., Sauter, G., Quaas, A. (2016) Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. Molecular Medicine Reports, 14(2): 1443-1450

Nepple, K.G., O'Donnell, M.A. (2009) The optimal management of T1 high-grade bladder cancer. Canadian Urological Association Journal, 3(6-S4): S188-192

Orsola, A., Trias, I., Raventós, C.X., Español, I., Cecchini, L., Búcar, S., Salinas, D., Orsola, I. (2005) Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (t1a/b/c) in BCG-treated and BCG-non-treated patients. European Urology, 48(2): 231-238

Palou, J., Sylvester, R.J., Faba, O.R., Parada, R., Peña, J.A., Algaba, F., Villavicencio, H. (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in t1g3 bladder cancer patients treated with bacillus calmette-guérin. European Urology, 62(1): 118-125

Raitanen, N., Aine, R., Rintala, E., Kallio, J., Rajala, P., Juusela, H., Tammela, T.L.J. (2002) Differences between local and review urinary cytology in diagnosis of bladder cancer: An interobserver multicenter analysis. European Urology, 41(3): 284-289

Soloway, M.S., Lee, C.T., Steinberg, G.D., Ghandi, A.A., Jewett, M.A.S. (2007) Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 25(4): 338-340

Sylvester, R.J., van der Meijden, A.P.M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D.W.W., Kurth, K. (2006) Predicting recurrence and progression in individual patients with stage TA T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven eortc trials. European Urology, 49(3): 466-477

1

Takenaka, A., Yamada, Y., Miyake, H., Hara, I., Fujisawa, M. (2008) Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. International Journal of Urology, 15(4): 309-313

van Rhijn, B.W.G., Burger, M., Lotan, Y., Solsona, E., Stief, C.G., Sylvester, R.J., Witjes, J., Zlotta, A.R. (2009) Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. European Urology, 56(3): 430-442

Youssef, R.F., Mitra, A.P., Bartsch, G., Jones, P.A., Skinner, D.G., Cote, R.J. (2009) Molecular targets and targeted therapies in bladder cancer management. World Journal of Urology, 27(1): 9-20
   

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.5633/amm.2019.0401_NE_RADI
objavljen u SCIndeksu: 24.02.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci

Acta medica Medianae (2018)
Ekspresija epigenetskog prigušivača EZH2 u rano invazivnom PT1 urotelnom karcinomu mokraćne bešike
Stojnev Slavica, i dr.

Vojnosanitetski pregled (2015)
Klinički tok karcinoma mokraćne bešike bez zahvatanja mišićnog sloja njenog zida posle transuretralne resekcije tumora sa ili bez naknadne intravezikalne aplikacije bacila Calmette-Guérin - uticaj pola i godina života bolesnika
Milošević Radovan, i dr.